Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Revenue(FY, 2016)

$230.1 M

Market capitalization(2018-02-13)

$1.2 B

Type

Public

Rockville, US

Founded

1996

Size (employees)

139 (est)

Website

sucampo.com

Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Report incorrect company information

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations

Rockville, US (HQ)

550 805 King Farm Blvd

Chiyoda, JP

NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho

Chuo Ward, JP

Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City

Kita Ward, JP

Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi

Sanda-shi, JP

4-1 Techno-Park

Zug, CH

22 Baarerstrasse

Show all (7)

Report incorrect company information

Sucampo Pharmaceuticals Financials and Metrics

Sucampo Pharmaceuticals Financials

Sucampo Pharmaceuticals's revenue was reported to be $230.06 m in FY, 2016 which is a 50.2% increase from the previous period.

Summary

USD
Revenue (Q3, 2017)	61.3 m
Gross profit (Q3, 2017)	43.8 m
Gross profit margin (Q3, 2017), %	71.5%
Net income (Q3, 2017)	10.4 m
EBIT (Q3, 2017)	21.2 m
Market capitalization (13-Feb-2018)	1.2 b
Cash (30-Sep-2017)	75 m

Sucampo Pharmaceuticals's current market capitalization is $1.2 b.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	89.6 m	115.5 m	153.2 m	230.1 m
Revenue growth, %		29%	33%	50%
Cost of goods sold	12.4 m	16.3 m	36.7 m	76 m
Gross profit	77.2 m	99.2 m	116.4 m	154.1 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue	21.2 m	22.2 m	24.1 m	31.5 m	29.5 m	34.9 m	33.4 m	47.2 m	52 m	57.9 m	56.3 m	59.9 m	61.3 m
Cost of goods sold	6.3 m	3.5 m	3.8 m	5 m	6.1 m	7.3 m	5.3 m	23.3 m	20.4 m	15.6 m	16.9 m	17 m	17.4 m
Gross profit	14.9 m	18.6 m	20.3 m	26.5 m	23.4 m	27.6 m	28.2 m	23.9 m	31.6 m	42.3 m	39.4 m	42.9 m	43.8 m
Gross profit Margin, %	70%	84%	84%	84%	79%	79%	84%	51%	61%	73%	70%	72%	72%

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	44.1 m	71.6 m	108.3 m	198.3 m
Accounts Receivable	5.4 m	5.3 m	22.8 m	43 m
Inventories	4 m	3.4 m	8.9 m	23.5 m
Current Assets	113.4 m	122.3 m	251.4 m	307.2 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	39.9 m	56.1 m	53.5 m	56.1 m	59.6 m	71.3 m	91.5 m	130.1 m	128 m	128.5 m	243.5 m	84.7 m	75 m
Accounts Receivable	2.7 m	4.4 m	4.8 m	8.5 m	8.2 m	8.2 m	6.7 m	16.1 m	18.2 m	20.7 m	20.5 m	19.8 m	33.1 m
Inventories	261 k	455 k	423 k	133 k	328 k	308 k	296 k	24.4 m	21.6 m	24.2 m	23 m	23.1 m	34.7 m
Current Assets	105.7 m	122.6 m	119.3 m	124.1 m	120.9 m	136.7 m	161.4 m	228.1 m	237.7 m	237.5 m	322.4 m	165.1 m	190.1 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	6.4 m	13.1 m	33.4 m	18.5 m
Depreciation and Amortization	1.5 m		10.6 m	45.7 m
Inventories	(163 k)		(1.4 m)	(1.2 m)
Accounts Payable	2.2 m		(1.7 m)	(2.8 m)

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017
Net Income	1.3 m	675 k	1.6 m	1.5 m	6.4 m	9.6 m	7.2 m	(4.1 m)	(832 k)	8.1 m	4.6 m	10.4 m
Inventories			423 k	133 k	328 k	308 k	296 k	24.4 m	21.6 m	24.2 m		34.7 m
Accounts Payable			5.6 m	5.9 m	1.4 m	3.9 m	4.9 m	5.1 m	6.2 m	7.9 m	8 m	6.2 m